iPS-KYOU, has been obtained in the Shinya Yamanaka laboratory (Kyoto University, Japan) by retroviral reprogramming of adult female skin fibroblasts. The iPS-KYOU cell line was purchased from the ATCC cell bank (KYOU-DXR0109B, ACS-1023™, ATCC®, United States).
iPS-AFS17, human Induced Pluripotent Stem Cells, obtained by lentiviral reprogramming of amniotic fluid stem cells by Dashinimaev et al. (2017) (link).
iPS-DP human Induced Pluripotent Stem Cells, obtained by lentiviral reprogramming of dermal papilla cells (Muchkaeva et al., 2014 (link)).
iPS-DYP0730, human Induced Pluripotent Stem Cells, derived from dermal fibroblasts obtained from ATCC CCL-54 Detroit 532, a human Down syndrome cell line. The iPS-DYP0730 cell line was purchased from the ATCC cell bank (ACS-1003™, ATCC®, United States).
For all pluripotent stem cell passaging, we used ACCUTASE™ сell detachment solution (Stem Cell Technologies) and Rock-inhibitor Y-27632 (5 μM; Abcam), the plastic surface being pre-coated with Matrigel solution (1/40 in DMEM/F12) (Corning). The cells were cultured in mTeSR™1 medium (Stem Cell Technologies) at 37°C in a CO2-incubator with 5% CO2 and 100% humidity.
Free full text: Click here